Biography

Erik M. Stang, Ph.D., is a patent agent in the firm’s Chemical Patent Prosecution group, focusing on patent preparation, patent prosecution, and providing technical consulting for domestic and international clients in a wide array of technical areas, including pharmaceuticals (small molecules and biologics), organic synthesis, catalysis, biotechnology, polymers, and nanomaterials.

Prior to joining the firm in 2014, Dr. Stang worked as a Research Investigator in oncology chemistry drug discovery at Bristol-Myers Squibb where he worked on both early and late stage research programs in the cancer therapeutic area, including protein-protein interaction inhibitors and small molecule-protein hybrid therapies. These medicinal chemistry programs included small molecule, millamolecular, and biologic research areas.

Dr. Stang completed his doctoral studies at the University of Illinois Urbana-Champaign. There, he developed and applied carbon-hydrogen activation reactions in complex molecule synthesis, including the synthesis of members of the erythronolide macrolide antibiotics and dehydrogentive Diels-Alder reactions.

Education

  • University of Illinois Urbana-Champaign (Ph.D.)
    • Organic Chemistry
  • James Madison University (B.S.)
    • Chemistry

Services

Professional Affiliations

  • American Chemical Society

Accolades

  • Bristol-Myers Squibb Graduate Fellowship, 2010
  • R.C. Fuson Travel Award, 2010
  • Roche Excellence in Chemistry Award, 2009
  • Pfizer Graduate Fellowship, 2008
  • R.C. Fuson Graduate Fellowship, 2007
  • Roger Adams Graduate Fellowship, 2006
  • Pfizer Undergraduate Research Fellowship, 2005
  • American Institute of Chemists Award, 2005
  • National Science Foundation Research Experience for Undergraduates Fellowship, 2003

Citations

Speeches:

  • “Engineering Payloads for Antibody-Drug Conjugates” Bristol-Myers Squibb Lawrenceville Discovery Chemistry Seminar Series, October 2013, Lawrenceville, NJ.
  • “C–H Oxidation Reactions in Complex Molecule Synthesis: Application and Development” Bristol-Myers Squibb Graduate Fellowship Award Symposium, April 2011, Lawrenceville, NJ.
  • “Total Synthesis and Study of 6-deoxyerythronolide B via Late-Stage C–H Oxidations” 59th Natural Products Gordon Research Conference, July 2010, Tilton, NH.
  • “Total Synthesis and Study of 6-deoxyerythronolide B via Late-Stage C–H Oxidations” 23rd Annual Allerton Research Conference, 2009, Monticello, IL.
  • “Total Synthesis and Study of 6-deoxyerythronolide B via Late-Stage C–H Oxidations” Roche Symposium: Excellence in Chemistry, 2009, Nutley, NJ.
  • "Cyclopropane Fragmentation Strategies for the Assembly of Nitrogenous Heterocycles" ACS National Meeting, Chemical Education Session, August 28th 2005, Washington, DC.
  • "Cyclopropane Fragmentation Strategies for the Assembly of Nitrogenous Heterocycles" Pfizer Global Research & Development, Summer Undergraduate Research Fellowship Program, September 30, 2005, Groton, CT.
  • “Synthesis of Complex Metal Oxides via Molten Hydroxide Fluxes” JMU National Science Foundation Research Experience for Undergraduates, August 5, 2004, Harrisonburg, VA.
  • Publications:
  • “Total Synthesis and Study of 6-deoxyerythronolide B by Late-Stage C–H Oxidation.” Nature Chemistry, 2009, 1, 547-551.
  • “On the Macrocyclization of the Erythromycin Core: Preorganization is Not Required.” Angewandte Chemie International Edition, 2011, 50, 2094-2097.
  • “Molecular Complexity via C–H Activation: A Dehydrogenative Diels-Alder Reaction.” J. Am. Chem. Soc. 2011, 33, 14892-14895.
  • “Preparation of Peptide IAP Antagonists for Cancer Treatment.” U.S. Pat. Appl. Publ. 2013, US2013/0338081.

Industries